Health Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo, after Australian TGA clearances

Health Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo, after Australian TGA clearances

Health Canada approved Eli Lilly’s oral GLP-1 medication Foundayo for obesity and weight-related health issues. The approval follows earlier clearances by Australia’s Therapeutic Goods Administration, which had already authorized the daily tablet for adults with type 2 diabetes and obesity, providing a new oral option alongside existing injectable treatments. The Therapeutic Goods Administration’s decisions were reported by multiple Australian health outlets, noting that Foundayo joins Novo Nordisk’s Wegovy tablet as a prescription-only GLP-1 therapy available to patients later in the year.

参与者

Therapeutic Goods Administration Foundayo Lilly Samantha Hocking National Association of Clinical Obesity Services Lilly Australia Dr Manny Simons

地点

Australia
总体结论: 部分确认 置信度: 71% 声明: 4
摘要

All four claims regarding Eli Lilly’s oral GLP-1 drug Foundayo were partially confirmed. The Therapeutic Goods Administration approved Foundayo for adults with type 2 diabetes and obesity in Australia. The approval introduces a second daily GLP-1 weight-loss pill to the Australian market alongside Novo Nordisk’s Wegovy tablet. Foundayo, or orforglipron, will be available for prescription in Australia within days. The drug provides a new daily tablet option for weight management and diabetes.

登录或订阅以查看完整分析,包括声明、来源和时间线验证。

本部分包含基于外部来源的自动化断言核查,可能存在不准确之处。

文章

2026年十一月18日
2 篇总计
Health Canada approves new Eli Lilly GLP-1 pill for weight loss
Health Canada approves new Eli Lilly GLP-1 pill for weight loss

Global News • 11月18日 21:12

Health Canada approved Eli Lilly’s daily oral GLP-1 medication Foundayo for obesity and weight-related health issues, with availability expected in pharmacies in January.

可信度 88% 操纵 8% 中立
Foundayo approval a welcome addition to GLP-1 treatment options
Foundayo approval a welcome addition to GLP-1 treatment options

Diabetes Australia • 11月18日 00:43

The Therapeutic Goods Administration has approved Foundayo, an oral GLP-1 receptor agonist, offering a daily tablet option for eligible adults with type 2 diabetes and obesity.

可信度 92% 操纵 8% 中立
2026年十一月17日
2 篇总计
1 to hit Australian shelves within days
1 to hit Australian shelves within days

Royal Australian College of General Practitioners (RACGP) • 11月17日 05:34

Eli Lilly's oral GLP-1 medication orforglipron, sold as Foundayo, has been approved by the Therapeutic Goods Administration and will be available for prescription within days, offering a new option for weight management and type-2 diabetes treatment.

可信度 88% 操纵 8% 中立
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained

Nine.com.au • 11月17日 02:45

The Therapeutic Goods Administration has cleared Eli Lilly’s Foundayo for weight management and type 2 diabetes, adding to Novo Nordisk’s Wegovy tablet, with both drugs requiring prescriptions and expected to reach patients later this year.

可信度 88% 操纵 8% 中立
2026年十一月16日
1 篇总计
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use

7NEWS • 11月16日 22:38

The Therapeutic Goods Administration has authorized the oral GLP-1 medication Foundayo, developed by Lilly, for weight loss and type 2 diabetes treatment, with availability expected within days.

可信度 88% 操纵 12% 中立